Anti-retroviral drugs

Instead, less traditional measures called surrogate endpoints are used to evaluate effectiveness. These are laboratory findings or signs that may not be a direct measurement of how a patient feels, functions, or survives, but are considered likely to predict benefit. For example, a surrogate endpoint could be the lowering of HIV blood levels for short periods of time with anti-retroviral drugs. 

The human rights campaign for access to anti-retroviral drugs... 

St. John s wort. Preliminary reports indicate that St. John s wort may interfere with the anti-tumor drugs etoposide (VePesid), teniposide (Vumon), mitoxantrone (Novantrone), and doxombicin (Adriamycin). This herb also lowers the amount of indinavir, an anti-retroviral drug used to treat HIV/AIDS, in the blood. Because St. John s wort likely reduces the effect of other anti-retro-viral drugs as well, people being treated for AIDS should avoid this herb. 

Cellular reservoirs and anatomical sanctuary sites, such as the CNS, hamper HTV-l treatment and allow HTV-l to persist. To these ends, the SCID mouse model was modified to allow spread of HTV-1 infection betw een human MDM in mouse brain tissue behind an intact BBB. This model permitted comparative assessment of different anti-retroviral drugs by measurements of viral load and numbers of infected human macrophages (Limoges et al., 2000 Limoges et al., 2001). New drug delivery systems across the BBB and novel neuropro tec five therapeutics are under investigation (Persidsky et al., 2001 Dou et al., 2003 Dou et al., 2005). 

Limoges J, Poluektova L, Ratanasuwan W, Rasmussen J, Zelivyan-skaya M, McClemon DR, Lanier ER, Gendelman HE, Persidsky Y (2001) The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. Virology 281 21-34. 

Table 1 Conditions for the chromatographic analysis of anti-retroviral drugs.

With the implementation of the PNM, Brazil expanded a strategic project for the technological development of medicines, initially through public production of essential medicines by laboratories belonging to the SUS (currently 19 SUS public laboratories). Two notable health policies in this initial period were investments by the Ministry of Health to allow public laboratories to produce less-expensive versions of anti-retroviral drugs, beginning in 1996, and the implementation of the Generic Medicines Law in 1999. 

---